Corcept Therapeutics Incorporated Cash Flow Quality Index
Corcept Therapeutics Incorporated cash flow quality index. Corcept Therapeutics Incorporated (CORT) has a Cash Flow Quality Index of 0.39x as of December 2025. Operating cash flow of $38.45 Million is below net income of $98.17 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial agility of Corcept Therapeutics Incorporated to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Corcept Therapeutics Incorporated (2016–2025)
Cash flow quality index of Corcept Therapeutics Incorporated from 2016 to 2025. Historical Cash Flow Quality Index for Corcept Therapeutics Incorporated across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore cash flow to debt ratio of Corcept Therapeutics Incorporated to assess how comfortably operating cash covers total debt obligations.
Corcept Therapeutics Incorporated Cash Flow Quality Index by Year (2016–2025)
Corcept Therapeutics Incorporated cash flow quality index by year from 2016 to 2025. Year-by-year earnings quality comparison for Corcept Therapeutics Incorporated. For the full cash flow conversion analysis, see CORT operating cash flow.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.45x | $142.00 Million | $98.17 Million | ▲ +3.1% |
| 2024 | 1.40x | $198.07 Million | $141.21 Million | ▲ +17.2% |
| 2023 | 1.20x | $127.04 Million | $106.14 Million | ▲ +0.9% |
| 2022 | 1.19x | $120.32 Million | $101.42 Million | ▼ -20.5% |
| 2021 | 1.49x | $167.89 Million | $112.51 Million | ▲ +4.1% |
| 2020 | 1.43x | $151.97 Million | $106.01 Million | ▼ -0.8% |
| 2019 | 1.45x | $136.12 Million | $94.18 Million | ▼ -5.8% |
| 2018 | 1.53x | $115.67 Million | $75.41 Million | ▲ +225.0% |
| 2017 | 0.47x | $60.94 Million | $129.12 Million | ▼ -79.1% |
| 2016 | 2.26x | $18.39 Million | $8.14 Million | — |